       Board of Directors
George M. Milne Jr., Ph.D.Chair, Rib-X Pharmaceuticals, Inc.
George M. Milne, Jr., Ph.D. has served on our board of directors since January 2004. He has served as chairman of our board of directors since May 2010 and previously served as executive chairman of our board of directors from June 2008 to May 2010. Since January 2003, Dr. Milne has been a venture partner of Radius Ventures, LLC. From 1970 to July 2002, Dr. Milne held various management positions with Pfizer Corporation, including most recently Executive Vice President, Pfizer Global Research and Development and President, Worldwide Strategic and Operations Management. Dr. Milne was also a Senior Vice President of Pfizer Inc. and a member of the Pfizer Management Council. He was President of Central Research from 1993 to July 2002 with global responsibility for Pfizer’s Human and Veterinary Medicine Research and Development. Dr. Milne received his Ph.D. in chemistry from Massachusetts Institute of Technology and his B.S. from Yale University. Dr. Milne is a director of Athersys Inc., Charles River Laboratories, Inc. and Mettler-Toledo International Inc. and also serves on the board of directors of several private companies. He was previously a director of Aspreva, Inc., Conor Medsystems, Inc. and MedImmune, Inc. We believe that Dr. Milne possesses specific attributes that qualify him to serve as a member of our board of directors, including more than 30 years experience in senior executive management roles with large, international businesses. In addition, because Dr. Milne has served on many boards of directors, we believe he has substantial experience regarding how boards can and should effectively oversee and manage companies, and a significant understanding of governance issues.
Mark LeuchtenbergerPresident and Chief Executive Officer, Rib-X Pharmaceuticals, Inc.
Mark Leuchtenberger has been our President, Chief Executive Officer and a member of our board of directors since March 2010, bringing experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. Prior to joining us, he served as President and Chief Executive Officer of Targanta Therapeutics Corporation, a biopharmaceutical company, from September 2006 until August 2009, following Targanta’s acquisition. As President and Chief Executive Officer at Targanta, he led its initial public offering in 2007 and its acquisition in 2009. From March 2002 to August 2006, Mr. Leuchtenberger served as the President and Chief Executive Officer of Therion Biologics Corporation, a privately-held cancer vaccine company. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Idec Inc., where he led the Avonex development and launch in the United States and subsequently managed North American and international commercial operations. Mr. Leuchtenberger received his M.B.A. from the Yale School of Management and his B.A. from Wake Forest University. He currently serves on the Executive Committee of the Massachusetts Biotechnology Council Board of Directors and as a trustee for Beth Israel Deaconess Medical Center. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. We believe that Mr. Leuchtenberger possesses specific attributes that qualify him to serve as a member of our board of directors, including the perspective and experience he brings as our Chief Executive Officer, which brings historic knowledge, operational expertise and continuity to our board of directors, and his prior executive experience as chief executive officer of two previous biotechnology companies.
C. Boyd ClarkeRetired President and Chief Executive Officer, Neose Technologies, Inc.
C. Boyd Clarke has served on our board of directors since July 2004 and has been the chairman of our audit committee since August 2007. Since September 2007, Mr. Clarke has been a venture advisor to ProQuest Investments, a healthcare venture capital firm. From April 2002 to June 2006, Mr. Clarke was president and chief executive officer of Neose Technologies, Inc., a publicly-traded biotechnology company focused on the development of protein therapeutics. Mr. Clarke served on the board of directors of Neose from 2002 to May 2007. From December 1999 through March 2002, Mr. Clarke was president and chief executive officer of Aviron, Inc., a biotechnology company developing vaccines, which was acquired by MedImmune, Inc., and was also chairman from January 2001 through March 2002. From 1998 through 1999, Mr. Clarke was chief executive officer and president of U.S. Bioscience, Inc., a biotechnology company focused on products to treat cancer, which was also acquired by MedImmune, Inc. Mr. Clarke served as president and chief operating officer of U.S. Bioscience, Inc. from 1996 to 1998. From 1977 to 1996, Mr. Clarke held a number of positions at Merck & Co., Inc., including being the first President of Pasteur-Merieux MSD, and most recently as vice president of Merck Vaccines. Mr. Clarke was formerly a director of the Biotechnology Industry Association. He is currently chairman of the board of directors of QLT Inc., publicly-traded biotechnology company. He also serves on the board of directors of NovaDigm Therapeutics, Inc., Palkion, Inc. and Ligocyte Pharmaceuticals, Inc., and as chairman of the board of Mersana Therapeutics, Inc., all of which are privately-held biotechnology companies. Mr. Clarke received his B.S. in biochemistry and his M.A. in history from the University of Calgary. We believe that Mr. Clarke possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience building, investing in and growing biotechnology companies. In addition, because Mr. Clarke has served on many boards of directors, we believe he has substantial experience regarding how boards can and should effectively oversee and manage companies, and a significant understanding of governance issues.
Cecilia Gonzalo
Cecilia Gonzalo has served on our board of directors since February 2010. Ms. Gonzalo has been a partner of Warburg Pincus & Co. and a member and managing director of Warburg Pincus LLC since January 2010. She was previously a principal of Warburg Pincus LLC from January 2006 to December 2009. She joined Warburg Pincus in 2001 and focuses on healthcare investments in the pharmaceuticals, biotechnology and healthcare services sectors. Prior to joining Warburg Pincus, Ms. Gonzalo worked at Goldman Sachs in the Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. She received her B.A. cum laude in biochemical sciences from Harvard College and her M.B.A. from Harvard Business School. Ms. Gonzalo is a director of Allos Therapeutics, Inc. and Talon Therapeutics, Inc. Ms. Gonzalo was previously a director of several biopharmaceutical companies, including Prestwick Pharmaceuticals, Inc. and Eurand N.V. We believe that Ms. Gonzalo possesses specific attributes that qualify her to serve as a member of our board of directors, including experience building, investing in and growing biotechnology companies. In addition, because Ms. Gonzalo has served on several boards of directors of public and private companies, we believe she has substantial experience regarding how boards can and should effectively oversee and manage companies, and a significant understanding of governance issues.
Jonathan Leff
Jonathan S. Leff has served on our board of directors since April 2003. Mr. Leff has been a partner of Warburg Pincus & Co. and a member and managing director of Warburg Pincus LLC since January 2000. Mr. Leff joined Warburg Pincus in 1996. Prior to joining Warburg Pincus, he was a consultant at Oliver, Wyman & Co. Mr. Leff received his A.B. in Government from Harvard College and his M.B.A. from the Stanford University Graduate School of Business. Mr. Leff is a director of Allos Therapeutics, Inc., InterMune, Inc., Sophiris Bio, Inc. and Talon Therapeutics, Inc. as well as several private companies. He is also a member of the boards of directors of several industry groups and non-profit organizations, including the Biotechnology Industry Organization, the National Venture Capital Association and the Spinal Muscular Atrophy Foundation, and a member of the board of visitors of Columbia University Medical Center. Mr. Leff was previously a director of Altus Pharmaceuticals Inc., Inspire Pharmaceuticals, Inc., Neurogen Corporation, Sunesis Pharmaceuticals, Inc. and ZymoGenetics, Inc. as well as several private companies. We believe that Mr. Leff possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience building, investing in and growing biotechnology companies and extensive experience in finance, capital markets and investing. In addition, because Mr. Leff has served on many boards of directors, we believe he has substantial experience regarding how boards can and should effectively oversee and manage companies, and a significant understanding of governance issues.
Harry H. Penner Jr., J.D., L.L.M.Chairman and Chief Executive Officer, Nascent Bioscience, L.L.C.
Harry H. Penner Jr., J.D., L.L.M. has served on our board of directors since June 2001 and has been the chairman of our compensation committee since January 2009. Mr. Penner served as chairman of our board of directors from June 2001 until June 2008. Mr. Penner is chairman and chief executive officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new biotechnology companies, since October 2001. Since August 2008, Mr. Penner has been the chief executive officer and chairman of the board of directors of New Haven Pharmaceuticals, Inc. From December 2004 to October 2007, Mr. Penner was chief executive officer and chairman of the board of directors of Marinus Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company. From 1993 to 2001, Mr. Penner was president, chief executive officer and vice chairman of Neurogen Corporation. From 1985 to 1993, Mr. Penner was an executive vice president of Novo Nordisk A/S, serving from 1988 to 1993 as executive vice president for North America and president, Novo Nordisk of North America, and from 1985 to 1988 as the company’s executive vice president and general counsel in Denmark. He has served as bioscience advisor to the Governor and the State of Connecticut, as co-chairman of Connecticut United for Research Excellence, and as chairman of the Connecticut Board of Governors of Higher Education and the Connecticut Technology Council. Mr. Penner serves on the board of directors of Celldex Therapeutics, Inc., New Haven Pharmaceuticals, Inc. (of which he is chairman), Prevention Pharmaceuticals, Inc. (of which he is chairman) and Affinimark Technologies, Inc. (of which he is chairman) and Marinus Pharmaceuticals, Inc. In addition to having served on the board of directors of privately held biotechnology companies, Mr. Penner served on the board of Altus Pharmaceuticals, Inc. until October 2009. Mr. Penner received his B.A. from the University of Virginia, his J.D. from Fordham University School of Law, and his L.L.M. in international law from New York University School of Law. We believe that Mr. Penner possesses specific attributes that qualify him to serve on our board of directors, including experience building, investing in and growing biotechnology companies and more than 20 years experience in senior executive management roles with large, international businesses. In addition, because Mr. Penner has served on many boards of directors, we believe he has substantial experience regarding how boards can and should effectively oversee and manage companies, and a significant understanding of governance issues.
|
